Foresite Capital Management V LLC Grows Stock Position in Lyell Immunopharma, Inc. $LYEL

Foresite Capital Management V LLC lifted its position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 17.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 477,078 shares of the company’s stock after acquiring an additional 70,426 shares during the quarter. Lyell Immunopharma accounts for approximately 7.1% of Foresite Capital Management V LLC’s holdings, making the stock its 5th largest position. Foresite Capital Management V LLC’s holdings in Lyell Immunopharma were worth $7,748,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in LYEL. ARCH Venture Management LLC bought a new position in Lyell Immunopharma during the second quarter worth $16,113,000. RBF Capital LLC bought a new stake in Lyell Immunopharma during the second quarter valued at $884,000. Marshall Wace LLP bought a new stake in Lyell Immunopharma during the second quarter valued at $94,000. Bridgeway Capital Management LLC acquired a new stake in shares of Lyell Immunopharma during the second quarter worth $159,000. Finally, Orbimed Advisors LLC bought a new position in shares of Lyell Immunopharma in the 2nd quarter worth about $457,000. 66.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Lyell Immunopharma

In related news, CEO Lynn Seely sold 7,455 shares of Lyell Immunopharma stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total value of $174,372.45. Following the sale, the chief executive officer directly owned 74,266 shares in the company, valued at $1,737,081.74. This trade represents a 9.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Gary K. Lee sold 1,671 shares of the business’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total transaction of $39,084.69. Following the transaction, the insider directly owned 16,938 shares of the company’s stock, valued at $396,179.82. The trade was a 8.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 11,310 shares of company stock worth $264,285 in the last ninety days. 22.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

LYEL has been the subject of several research reports. Citizens Jmp assumed coverage on shares of Lyell Immunopharma in a report on Monday, March 9th. They issued a “market outperform” rating and a $34.00 price target for the company. HC Wainwright raised shares of Lyell Immunopharma from a “neutral” rating to a “buy” rating and raised their target price for the stock from $20.00 to $45.00 in a report on Tuesday, December 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $39.50.

Lyell Immunopharma Price Performance

Shares of NASDAQ LYEL opened at $21.25 on Monday. The firm has a market capitalization of $451.44 million, a PE ratio of -1.30 and a beta of -0.14. Lyell Immunopharma, Inc. has a 1-year low of $7.65 and a 1-year high of $45.00. The business’s fifty day moving average price is $24.13 and its two-hundred day moving average price is $21.61.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($7.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.15) by ($5.53). The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.02 million. Lyell Immunopharma had a negative net margin of 762,355.56% and a negative return on equity of 90.52%. Equities research analysts expect that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Lyell Immunopharma Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.